Long-Term Sulfonylurea Response in KCNJ11 Neonatal Diabetes

计划入组 90 人 · 首次发布于 2015 年 12 月 8 日

Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome

计划入组 21 人 · 首次发布于 2023 年 3 月 2 日

Effect of Food Composition on Postprandial Insulin Secretion in Neonatal Diabetes

计划入组 16 人 · 首次发布于 2016 年 10 月 3 日

KCNT1 inhibitor (Praxis/UCB)

KCNT1 targeting therapeutic (epilepsy)

BK channel modulator (KCNMA1-linked channelopathies)

Congenital Hyperinsulinism Pipeline Shows Promise with Multiple Therapies Advancing Through Clinical Development

Organoid Technology Advances Diabetes Research with Sophisticated 3D Models and Therapeutic Applications

Cerevance Reports Positive Phase 1 Results for Novel KCNK13 Inhibitor CVN293 Targeting Neuroinflammation